Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Defence Therapeutics (OTCQB: DTCFF) has appointed Dr. Mark Lambermon as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience in pharmaceutical R&D, biotech innovation, and commercial manufacturing, having held key positions at AbbVie Inc. and Baxter Healthcare.
Dr. Lambermon's expertise includes leading global CMC programs, supplier oversight, and implementing GMP-compliant quality systems. He holds a PhD in Cellular Biology from the University of Basel and has completed postdoctoral fellowships at prestigious institutions. As part of his compensation, he was granted 100,000 stock options at $0.80 per share, vesting immediately with a three-year exercise period.
Defence Therapeutics (OTCQB: DTCFF) ha nominato il dottor Mark Lambermon come Responsabile della Qualità e delle Operazioni. Il Dottor Lambermon porta oltre 20 anni di esperienza in R&D farmaceutica, innovazione biotecnologica e produzione commerciale, avendo ricoperto ruoli chiave presso AbbVie Inc. e Baxter Healthcare.
L'esperienza del Dottor Lambermon comprende la guida di programmi CMC a livello globale, supervisione dei fornitori e l'implementazione di sistemi di qualità conformi alle GMP. Possiede un dottorato in biologia cellulare dall'Università di Basilea e ha completato fellowship post-dottorali in rinomate istituzioni. Nell'ambito del suo compenso, gli sono state attribuite 100.000 stock option al prezzo di $0,80 per azione, che si vanno immediatamente a maturare con un periodo di esercizio di tre anni.
Defence Therapeutics (OTCQB: DTCFF) ha designado a el Dr. Mark Lambermon como Jefe de Calidad y Operaciones. El Dr. Lambermon aporta más de 20 años de experiencia en I+D farmacéutica, innovación biotecnológica y fabricación comercial, habiendo ocupado puestos clave en AbbVie Inc. y Baxter Healthcare.
La experiencia del Dr. Lambermon incluye liderar programas globales de CMC, supervisión de proveedores e implementación de sistemas de calidad conforme a GMP. Posee un PhD en Biología Celular de la Universidad de Basilea y ha realizado becas posdoctorales en instituciones de renombre. Como parte de su compensación, se le otorgaron 100.000 opciones sobre acciones a un precio de $0,80 por acción, con ejecución inmediata y un periodo de ejercicio de tres años.
Defence Therapeutics (OTCQB: DTCFF)는 품질 및 운영 책임자로 마크 램버몬 박사를 임명했습니다. 램버몬 박사는 제약 R&D, 생명공학 혁신 및 상업 제조 분야에서 20년이 넘는 경력을 보유하고 있으며, AbbVie Inc.와 Baxter Healthcare에서 핵심 직책을 역임했습니다.
램버몬 박사의 전문 분야로는 글로벌 CMC 프로그램 주도, 공급업체 관리, GMP 준수 품질 시스템의 구현이 포함됩니다. 바젤 대학교에서 세포생물학 박사 학위를 취득했고, 저명한 기관에서 포닥 펠로우십을 마쳤습니다. 보상으로 10만 주의 스톡 옵션이 주어졌으며, 주당 가격은 $0.80이고 즉시 가용되며 3년의 행사 기간이 있습니다.
Defence Therapeutics (OTCQB: DTCFF) a nommé le docteur Mark Lambermon comme Responsable Qualité et Opérations. Le Dr Lambermon apporte plus de 20 ans d’expérience dans la R&D pharmaceutique, l’innovation biotechnologique et la fabrication commerciale, ayant occupé des postes clés chez AbbVIE et Baxter Healthcare.
L’expertise du Dr Lambermon inclut la conduite de programmes CMC globaux, la supervision des fournisseurs et la mise en place de systèmes de qualité conformes aux BPF. Il est titulaire d’un doctorat en biologie cellulaire de l’Université de Bâle et a mené des mandats postdoctoraux dans des institutions réputées. Dans le cadre de sa rémunération, il a reçu 100 000 options d’achat d’actions à 0,80 $ l’action, acquises immédiatement avec une période d’exercice de trois ans.
Defence Therapeutics (OTCQB: DTCFF) hat Dr. Mark Lambermon zum Leiter Qualität und Betrieb ernannt. Dr. Lambermon bringt über 20 Jahre Erfahrung in pharmazeutischer F&E, Biotech-Innovation und kommerzieller Fertigung mit und hat leitende Positionen bei AbbVie Inc. und Baxter Healthcare inne.
Seine Expertise umfasst die Leitung globaler CMC-Programme, Lieferantenaufsicht und die Implementierung GMP-konformer Qualitäts-Systeme. Er hält einen PhD in Zellbiologie von der Universität Basel und hat Postdoktorandentreffs an renommierten Instituten absolviert. Als Teil seiner Vergütung erhielt er 100.000 Mitarbeiteraktienoptionen zu einem Preis von 0,80 $ pro Aktie, die sofort vesten, mit einer Ausübungsfrist von drei Jahren.
Defence Therapeutics (OTCQB: DTCFF) عينت الدكتور مارك لامبرمون كالرئيس للجودة والعمليات. يجلب الدكتور لامبرمون أكثر من 20 عامًا من الخبرة في البحث والتطوير الدوائي والابتكار الحيوي والتصنيع التجاري، شغل خلالها مناصب رئيسية في AbbVIE و Baxter Healthcare.
تتضمن خبرته قيادة البرامج العالمية لـ CMC، والإشراف على الموردين، وتنفيذ أنظمة جودة تتوافق مع GMP. يحمل الدكتوراه في علم الخلية من جامعة بازل وأكمل زمالات ما بعد الدكتوراه في مؤسسات مرموقة. كجزء من تعويضه، مُنِحَ له 100,000 خيار أسهم بسعر 0.80 دولار للسهم، قابلة للتفعيل فورًا مع فترة ممارسة تبلغ ثلاث سنوات.
Defence Therapeutics (OTCQB: DTCFF) 任命 马克·兰伯蒙博士 为质量与运营主管。兰伯蒙博士在制药研发、生物技术创新与商业制造领域拥有超过20年经验，曾在 AbbVie Inc. 与 Baxter Healthcare 担任要职。
兰伯蒙博士的专长包括领导全球级的CMC项目、供应商监督以及建立符合GMP要求的质量体系。他在巴塞尔大学获得细胞生物学博士学位，并在知名研究机构完成博士后研究。作为薪酬的一部分，他获得100,000份股票期权，行权价为每股0.80美元，立即可行权，三年行权期。
- Appointment of highly experienced executive with 20+ years in pharmaceutical R&D and manufacturing
- Dr. Lambermon's expertise in regulatory compliance and GMP systems strengthens operational capabilities
- Immediate vesting of stock options aligns new executive's interests with shareholders
- Stock option grant of 100,000 shares creates minor dilution for existing shareholders
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building and leading Quality organizations across the full drug development lifecycle.
Dr. Lambermon held roles at AbbVie Inc., and Baxter Healthcare in Chicago, Illinois, where he led global CMC programs, supplier and CDMO qualification/oversight, and implemented GMP-compliant quality systems. Earlier in his career, Dr. Lambermon supervised Quality Control operations supporting FDA-regulated manufacturing at NantPharma and Monosol Inc. and contributed to the development of AAV-based gene therapies at Arthrogen BV in Amsterdam, The Netherlands.
"Mark's extensive expertise in Quality, regulatory compliance and Operations will be pivotal as we advance towards regulatory readiness," said Sébastien Plouffe, Founder and CEO of Defence Therapeutics. "He has broad experience designing fit-for-phase Quality systems, overseeing global supply chains, and prepare organizations for inspection readiness - exactly the leadership we need to support our next stage of growth as well as to secure strong partnerships with pharma."
"I'm thrilled to join Defence Therapeutics at this pivotal moment," said Dr. Lambermon. "With Accum®, we have a real chance to improve outcomes and quality of life for patients facing aggressive cancers. My priority is to build a scalable, phase-appropriate Quality organization so that our scientific innovation is matched by operational excellence, regulatory compliance, and-above all-patient safety."
Dr. Lambermon holds a PhD in Cellular Biology from the University of Basel, Switzerland, and completed postdoctoral fellowships at the University of Toronto and Radboud University in The Netherlands. He earned his BSc and MSc in Organic and Biochemistry at the University of Nijmegen in the Netherlands.
The Company has granted 100,000 incentive stock options to Dr. Lambermon (the "Options"), in accordance with the terms and conditions of Defence's Omnibus Incentive Plan. The Options are vested immediately and exercisable at a price of
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268741
FAQ
Who is the new Head of Quality and Operations at Defence Therapeutics (DTCFF)?
What is Dr. Lambermon's background and experience before joining Defence Therapeutics?
What stock options were granted to Dr. Lambermon by Defence Therapeutics?
How will Dr. Lambermon's appointment benefit Defence Therapeutics' development of Accum?
